Mont-Saint-Guibert (Belgium), December 8, 2023, 10.30pm CET / 4.30pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below.
On December 6, 2023, Nyxoah received a transparency notification from Deerfield Partners, L.P. indicating that Deerfield Partners, L.P. crossed the 3% threshold on November 30, 2023, after which Deerfield Partners, L.P. holds 856,085 shares, representing 2.99% of the total number of voting rights on November 30, 2023 (28,673,985).
The notification dated December 6, 2023 contains the following information:
A) Voting rights | Previous notification | After the transaction | |||
# of voting rights | # of voting rights | % of voting rights | |||
Holders of voting rights | Linked to securities | Not linked to the securities | Linked to securities | Not linked to the securities | |
James E. Flynn | 0 | 0 | 0 | 0.00% | 0.00% |
Deerfield Partners, L.P. | 899,300 | 856,085 | 0 | 2.99% | 0.00% |
Subtotal | 899,300 | 856,085 | 2.99% | ||
TOTAL | 856,085 | 0 | 2.99% | 0.00% |
Contact:
Nyxoah
David DeMartino, Chief Strategy Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.
+1 310 310 1313
Last Trade: | US$9.13 |
Daily Change: | 0.10 1.11 |
Daily Volume: | 23,753 |
Market Cap: | US$261.700M |
March 05, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB